All Pfizer articles
-
OpinionWhy companies are rushing to flatter Trump
Pharma firms are among many pausing diversity programmes and promising domestic investment
-
-
OpinionLetters: January 2024
Readers clarify the details of Pfizer’s future plans, muse on the philosophy of assembly theory and more
-
BusinessPharmaceuticals roundup 2023
Regulatory and pricing reforms have topped industry agendas in 2023, while weight loss drugs surged and Covid-19 therapies waned
-
BusinessRevolutionising RSV prevention
New vaccines and a long-acting antibody aim to protect older adults and babies from respiratory syncytial virus
-
BusinessPfizer to buy cancer biotech Seagen for $43 billion
Antibody-drug conjugate specialist will fill Pfizer’s cancer pipeline
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
OpinionThe shadow of drug resistance
Why do some medicines stop working, and can we avoid it for Covid-19 antivirals?
-
BusinessPharmaceuticals roundup 2021
It’s been another dramatic, pandemic-dominated year for the pharmaceutical industry
-
BusinessPfizer sues former employee for alleged trade secret theft
Chun Xiao Li downloaded thousands of confidential documents before resigning
-
BusinessCovid-19 antivirals surge forward
Promising results from Pfizer trial, while UK approves Merck & Co’s molnupiravir
-
OpinionWhere are the Covid-19 drugs?
Small molecules appear to be lagging behind development of vaccine and antibody treatments
-
BusinessUS grants Pfizer’s Covid-19 vaccine full approval
WHO calls for delay to booster programmes to allow more global distribution
-
BusinessPfizer backs protein degrader drugs with Arvinas deal
$1bn investment to commercialise breast cancer treatment
-
OpinionA rough guide to pharma partnership deals
Coronavirus vaccines are driving unusual collaborations with a range of benefits
-
BusinessPfizer–BioNTech vaccine gains emergency approvals in US, Canada and beyond
UK begins vaccinating vulnerable populations after early authorisation
-
BusinessUK grants Pfizer–BioNTech Covid-19 vaccine emergency approval
Regulators around the world working towards accelerated decisions on vaccine data
-
-
BusinessOxford–AstraZeneca vaccine joins others with promising interim data
Cheap and fridge-stable candidate at least 60% and up to 90% effective at preventing disease
-
BusinessModerna and Pfizer’s Covid-19 vaccines add more encouraging data
Pfizer–BioNTech reach safety threshold for emergency authorisation, while Moderna’s data peek suggests 95% efficacy